acyl-CoA dehydrogenase (NADPH)

(redirected from Medium-Chain Acyl-CoA Dehydrogenase)
Also found in: Acronyms.

ac·yl-CoA de·hy·dro·gen·ase (NADPH)

enzyme catalyzing the reversible reduction of enoyl-CoA derivatives of chain length 4-16, with NADPH as the hydrogen donor, forming acyl-CoA and NADP+.
Synonym(s): enoyl-CoA reductase
Farlex Partner Medical Dictionary © Farlex 2012

acyl-CoA de·hy·dro·gen·ase (NADPH)

(as'il-kō-ā dē-hī-droj'ĕ-nās)
Enzyme catalyzing the reversible reduction of enoyl-CoA derivatives of chain length 4-16, with NADPH as the hydrogen donor, forming acyl-CoA and NADP+.
Medical Dictionary for the Health Professions and Nursing © Farlex 2012
References in periodicals archive ?
MCAD deficiency is inherited as an autosomal recessive trait and is caused by mutations in the medium-chain acyl-CoA dehydrogenase (ACADM) gene, which is located on chromosome 1p31 and consists of 12 exons spanning 44 Kb [8].
Identification of new medium-chain acylcarnitines present in urine of a patient with medium-chain acyl-CoA dehydrogenase deficiency.
Population screening for the common G985 mutation causing medium-chain acyl-CoA dehydrogenase deficiency with Eu-labeled oligonucleotides and the DELFIA system.
Neonatal screening for medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in the Netherlands: the importance of enzyme analysis to ascertain true MCAD deficiency.
For example, one of the disorders included in the expanded panel, medium-chain acyl-CoA dehydrogenase deficiency (MCAD), involves a simple treatment (i.e., avoiding fasting); thus, proper medical management of a child identified with MCAD can be lifesaving.
Medium-chain Acyl-CoA dehydrogenase (MCAD) deficiency is an inherited enzyme deficiency.
For example, for medium-chain acyl-CoA dehydrogenase deficiency (MCADD), the ratios of acylcarnitines C8:C10, C8:C6, C8:C2, and C8:C12 have proven useful (1-5).
He was among the first to describe the fatal clinical phenotype and the first to identify neonatal metabolite abnormalities in medium-chain acyl-CoA dehydrogenase (MCAD) deficiency.
The range of detectable disorders includes medium-chain acyl-CoA dehydrogenase deficiency (MCAD), one of several related fatty acid oxidation disorders.
Myristic acid (C14) is used to detect defects in mediumchain FAO, such as medium-chain acyl-CoA dehydrogenase deficiency.
As a newborn-screening assay, MS/MS is not merely a method for detecting medium-chain acyl-CoA dehydrogenase (MCAD) deficiency (7), nor is it simply an improved method for accurate neonatal detection of PKU with a false-positive rate 10-fold lower than the best method previously available (8).

Full browser ?